Skip to main content
GI Innovation Inc. logo

GI Innovation Inc. — Investor Relations & Filings

Ticker · 358570 ISIN · KR7358570000 KO Professional, scientific and technical activities
Open in API
Filings indexed 344 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country KR South Korea
Listing KO 358570

About GI Innovation Inc.

https://www.gi-innovation.com/en/

GI Innovation Inc. is a bio-venture company that researches and develops innovative protein-based drugs. The company utilizes its proprietary GI-SMART™ platform to create novel biologics, focusing on immuno-oncology and immunology-related diseases. Its development pipeline includes key candidates such as GI-101, an immuno-oncology treatment, and GI-301 for IgE-mediated allergic diseases. The company's approach is guided by its 'Science, Strategy, Speed' (3S) strategy, which integrates basic science with translational research to accelerate drug development.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제1b/2상 임상시험계획 승인)
Regulatory Filings Classification · 85% confidence The document is a Korean stock exchange regulatory disclosure (“투자판단 관련 주요경영사항”) announcing and correcting details of a clinical trial plan approval. It is not a financial report (no financial statements), earnings release, management presentation, or other specific corporate transaction. It serves as a compliance announcement to investors and thus falls under the general “Regulatory Filings” category (RNS).
2026-05-29 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (전이성 거세저항성 전립선암 환자를 대상으로 GI102와 pasritamig 병용 요법의 항암 활성, 안전성 및 내약성을 평가하기 위한 제 1b/2상 임상시험계획 승인 신청)
Regulatory Filings Classification · 81% confidence The document is a Korean stock exchange disclosure (“투자판단 관련 주요경영사항”) correcting previously filed information about a clinical trial plan approval application (IND). It is not an annual or quarterly financial report, earnings release, management or board change, dividend or proxy material, nor a detailed investor presentation. Rather, it is a routine regulatory announcement of a material event and its correction, fitting the fallback “Regulatory Filings” category.
2026-05-28 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” (Quarterly Report) for the period January 1 to March 31, 2026 (1Q 2026). It contains detailed narrative business descriptions, financial tables, and substantive numerical results for the first quarter, consistent with a comprehensive interim/quarterly report rather than an earnings release or simple announcement. Therefore, it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
주식소각결정
Transaction in Own Shares Classification · 87% confidence The document is a corporate disclosure (in Korean) detailing the board’s decision to cancel (소각) treasury shares, including the number of shares, schedule, method, and related dates. This is effectively a disposal of the company’s own shares (treasury shares). Among the available categories, ‘Transaction in Own Shares’ (POS) covers share buybacks or disposals of treasury shares, which best fits this cancellation announcement.
2026-05-13 Korean
[기재정정]주식매수선택권부여에관한신고
Director's Dealing Classification · 70% confidence The document is a regulatory notification (‘신고’) concerning the grant of stock options (주식매수선택권) to company directors, executives and employees, with a correction to a prior filing. This is a disclosure of insider share‐option allocations, akin to insider transaction reporting rather than a financial report, capital financing update, or AGM material. Therefore it best fits the “Director’s Dealing” category (insider-related share transactions).
2026-05-13 Korean
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) ( GI102 제1/2상 임상시험계획 변경승인 )
Regulatory Filings Classification · 80% confidence The document is a Korean regulatory disclosure on the Korea Exchange titled “투자판단 관련 주요경영사항(임상시험계획 변경승인)” describing the approval of changes to a Phase 1/2 clinical trial plan. It is not an annual or interim report, earnings release, board/management announcement, financing update, dividend notice, or any of the other specific categories. It is a standalone regulatory announcement of an operational/clinical trial event that does not fit a more precise category, so it falls under the general “Regulatory Filings” fallback.
2026-04-23 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.